A novel, potent and selective MEK inhibitor (MEK1; IC₅₀=72 nM, MEK2; IC₅₀=58 nM). Inhibits AP-1 transcription activity. Blocks the production of inflammatory cytokines and matrix metalloproteinases.

1. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825: T.K. Nguyen et al; .Blood 109, 4006 (2007).

2. MEK inhibition enhances paclitaxel-induced tumor apoptosis: J.P. MacKeigan et al.; J. Biol. Chem. 275, 38953 (2000).